- UNION invited to present orismilast at the Dermatology Summit 2023
- Orismilast is a potent next-generation PDE4 inhibitor with broad anti-inflammatory properties in development as a first-in-class or best-in-class treatment for psoriasis, atopic dermatitis (AD) and hidradenitis suppurativa (HS)
- Access to recorded presentation available after the conference at UNION’s website
Hellerup, Denmark, 7 December 2022 – UNION therapeutics A/S (UNION), a privately-held, multi-asset, clinical stage, pharmaceutical development company focused on immunology and infectious diseases, today announced that Kim Kjøller, CEO of UNION therapeutics will present at the Entrepreneurial Company Showcase at the Dermatology Summit on 8 January 2023 at 12pm PST in San Francisco, CA, US.
A video recording of the presentation will afterwards be made available at UNION’s website.
Contacts
Morten Boesen, Chief Financial Officer, UNION therapeutics A/S
+45 2381 5487
Sarah Toft-Jørgensen, Director of Communications and IR, UNION therapeutics A/S
+45 5385 3044
About UNION therapeutics
UNION therapeutics is a privately held, multi-asset, clinical stage, pharmaceutical development company focused on immunology and infectious diseases. The company is currently working with two complementary chemistry classes, spanning immunology and microbiology with multiple candidates in clinical development. UNION is headquartered in Hellerup, Denmark, and led by an international team combining biotech entrepreneurs and seasoned pharma executives, with a track record of developing and launching more than fifteen marketed drugs. Read more at http://www.uniontherapeutics.com
